Regeneron Pharmaceuticals' phase 3 trial for its melanoma drug fianlimab, combined with cemiplimab, failed to meet the primary goal of significantly improving progression-free survival compared to Merck's Keytruda. Although the combination extended median progression-free survival by 5.1 months, it narrowly missed statistical significance, raising doubts about its effectiveness. This setback led to analyst downgrades and follows earlier disappointing trial results in lung cancer. A separate trial comparing fianlimab to a rival drug continues, but the recent failure raises concerns about the drug's commercial future.
Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free surviv...
Regeneron Pharmaceuticals reported that its late-stage trial for the skin cancer drug fianlimab did not meet the primary endpoint, failing to outperform Merck's Keytruda. This setback caused Regeneron's stock to fall significantly in premarket tradin...
Regeneron Pharmaceuticals has entered a strategic collaboration with Parabilis Medicines to develop Antibody-Helicon™ Conjugates (AHCs), a novel therapy class aimed at difficult-to-treat targets. Regeneron will invest $125 million upfront and potenti...
Regeneron's Phase 3 trial testing fianlimab (LAG-3 inhibitor) combined with cemiplimab (PD-1 inhibitor) as first-line treatment for unresectable or metastatic melanoma did not achieve statistical significance for its primary endpoint of improved prog...
At the 2026 Regeneron International Science and Engineering Fair, over $7 million in awards were given to more than 1,700 young STEM students from 67+ countries. Hikaru Kuribayashi, 17, won the top $100,000 prize for his simulation program predicting...
